1. Home
  2. PAC vs VTRS Comparison

PAC vs VTRS Comparison

Compare PAC & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Aeroportuario Del Pacifico

PAC

Grupo Aeroportuario Del Pacifico

N/A

Current Price

$259.76

Market Cap

11.7B

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$11.69

Market Cap

12.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAC
VTRS
Founded
1998
1961
Country
Mexico
United States
Employees
N/A
N/A
Industry
Aerospace
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7B
12.0B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
PAC
VTRS
Price
$259.76
$11.69
Analyst Decision
Buy
Hold
Analyst Count
6
6
Target Price
$245.00
$11.50
AVG Volume (30 Days)
99.4K
7.4M
Earning Date
10-20-2025
11-06-2025
Dividend Yield
4.44%
4.19%
EPS Growth
13.32
N/A
EPS
1.07
N/A
Revenue
$1,870,491,921.00
$14,124,400,000.00
Revenue This Year
$56.92
N/A
Revenue Next Year
$8.83
$1.16
P/E Ratio
$23.59
N/A
Revenue Growth
35.46
N/A
52 Week Low
$168.62
$6.85
52 Week High
$263.10
$12.78

Technical Indicators

Market Signals
Indicator
PAC
VTRS
Relative Strength Index (RSI) 72.13 69.15
Support Level $245.98 $10.67
Resistance Level $263.10 $11.83
Average True Range (ATR) 7.55 0.26
MACD 2.38 0.07
Stochastic Oscillator 90.75 88.31

Price Performance

Historical Comparison
PAC
VTRS

About PAC Grupo Aeroportuario Del Pacifico

Grupo Aeroportuario del Pacifico SAB de CV is engaged in the construction, development, and operation of airports in Mexico. The company's segment includes Guadalajara; Tijuana; Puerto Vallarta; San Jose del Cabo; Montego Bay; Hermosillo; Guanajuato and Other Airports. It generates maximum revenue from the Guadalajara segment.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: